Lung cancer is the leading cause of cancer death and the second most common cancer in the world. For years the standard treatment strategies of lung cancer have been surgery, chemotherapy, radiation therapy and targeted therapy. Recently, tumor immunotherapy is attracting the most attention among different therapeutic options for treatment of lung cancer. Both innate immunity and adaptive immunity play a crucial role in antitumor immune response. Lung cancer evades the immune response through multiple mechanisms. The consequence of crosstalks between tumor cells and non-malignant cells is reflected in tumor formation and maintenance as well as deficient response to therapy and multidrug resistance. The non-malignant cells in the microenvironment are known to promote tumorigenesis in all phases of cancer development. Researches are designed and carried out to further our understanding of the immunological evolution from precancerous lesions to invasive lung cancer, which is to enable immunological characteristics to be integrated with the findings of the substantial preclinical efforts to define malignancy of lung cancer.
In this Research Topic, we would like to discuss the current advances in the study of immunologic evolution in lung cancer. Based on these notions, this Research Topic aims to further our understanding of prevalence and timing of interaction between lung cancer and immune system and its potential impact on tumor evolution, especially from precancerous lesions to invasive lung cancer.
We welcome submissions of Original Research, Review, and Mini Review on the sub-topics below:
• Key subsets of T cells and B cells in malignant progression of lung cancer
• Immune cells and their role in the tumorigenesis of precancerous lesions of lung cancer
• Newly identified immunologic escape pattern in uncommon lung cancer subtypes
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Lung cancer is the leading cause of cancer death and the second most common cancer in the world. For years the standard treatment strategies of lung cancer have been surgery, chemotherapy, radiation therapy and targeted therapy. Recently, tumor immunotherapy is attracting the most attention among different therapeutic options for treatment of lung cancer. Both innate immunity and adaptive immunity play a crucial role in antitumor immune response. Lung cancer evades the immune response through multiple mechanisms. The consequence of crosstalks between tumor cells and non-malignant cells is reflected in tumor formation and maintenance as well as deficient response to therapy and multidrug resistance. The non-malignant cells in the microenvironment are known to promote tumorigenesis in all phases of cancer development. Researches are designed and carried out to further our understanding of the immunological evolution from precancerous lesions to invasive lung cancer, which is to enable immunological characteristics to be integrated with the findings of the substantial preclinical efforts to define malignancy of lung cancer.
In this Research Topic, we would like to discuss the current advances in the study of immunologic evolution in lung cancer. Based on these notions, this Research Topic aims to further our understanding of prevalence and timing of interaction between lung cancer and immune system and its potential impact on tumor evolution, especially from precancerous lesions to invasive lung cancer.
We welcome submissions of Original Research, Review, and Mini Review on the sub-topics below:
• Key subsets of T cells and B cells in malignant progression of lung cancer
• Immune cells and their role in the tumorigenesis of precancerous lesions of lung cancer
• Newly identified immunologic escape pattern in uncommon lung cancer subtypes
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
